An update on the treatment paradigm for non-clear cell renal cell carcinoma
Expert Review of Clinical Pharmacology · 2026
DOI: 10.1080/17512433.2026.2615995 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2026. Verfasst von Alessandro Rametta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Agents. Die Arbeit nennt 98 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Non - clear cell renal cell carcinoma (nccRCC) encompasses a heterogeneous group of rare malignancies, representing approximately 20-25% of all renal cancers. Unlike clear cell RCC (ccRCC), these subtypes - papillary, chromophobe, collecting duct, translocation, molecularly defined variants and others - display distinct biological behaviors, genetic profiles, and therapeutic sensitivities, which preclude a uniform treatment approach. AREAS COVERED: This review provides an updated overview of systemic therapy for nccRCC, integrating evidence from prospective trials, retrospective series, and translational research. For most of these histologies, immune checkpoint inhibitor (ICI) - based combinations (e.g. pembrolizumab - lenvatinib, nivolumab - cabozantinib or nivolumab-ipilimumab) have demonstrated the best activity. In chromophobe RCC (chRCC), also mechanistic target of rapamycin (mTOR) inhibition appears particularly relevant, whereas in collecting duct carcinoma and renal medullary carcinoma platinum-based chemotherapy continue to have an important role, with cabozantinib showing encouraging results. Novel biomarker-driven approaches are emerging for selected molecular subsets. EXPERT OPINION: Although remarkable progress has been achieved, the optimal therapeutic strategy for nccRCC remains undefined. Future efforts should focus on histology- and biomarker-driven clinical trials, molecular stratification, to optimize efficacy across subtypes. International collaboration is crucial to overcome the challenges posed by the rarity and biological heterogeneity of these tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
- Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
ORCID-Profile: Alessandro Rametta, Marco Stellato
Zitieren
APA
Rametta, A., Crippa, N., Rota, S., Gusmaroli, E., Stellato, M., Verzoni, E., Nuzzo, A., Claps, M., Guadalupi, V., & Procopio, G. (2026). An update on the treatment paradigm for non-clear cell renal cell carcinoma. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2026.2615995
Vancouver
Rametta A, Crippa N, Rota S, Gusmaroli E, Stellato M, Verzoni E, et al. An update on the treatment paradigm for non-clear cell renal cell carcinoma. Expert Review of Clinical Pharmacology. 2026. doi:10.1080/17512433.2026.2615995
BibTeX
@article{Rametta2026,
author = {Rametta, Alessandro and Crippa, Noemi and Rota, Simone and Gusmaroli, Eleonora and Stellato, Marco and Verzoni, Elena and Nuzzo, Amedeo and Claps, Melanie and Guadalupi, Valentina and Procopio, Giuseppe},
title = {An update on the treatment paradigm for non-clear cell renal cell carcinoma},
journal = {Expert Review of Clinical Pharmacology},
year = {2026},
doi = {10.1080/17512433.2026.2615995}
}
EUVIMED